Gastric acid suppression is associated with decreased erlotinib efficacy in non–small-cell lung cancer

MP Chu, S Ghosh, CR Chambers, N Basappa… - Clinical lung cancer, 2015 - Elsevier
Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …
被引用次数：119 相关文章

[引用][C] Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer

MP Chu, S Ghosh, CR Chambers, N Basappa… - Clinical Lung …, 2015 - cir.nii.ac.jp
Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell
Lung Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データを …

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer

MP Chu, S Ghosh, CR Chambers… - Clinical Lung …, 2015 - clinical-lung-cancer.com
Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non--Small-Cell Lung Cancer.

MP Chu, S Ghosh, CR Chambers… - Clinical Lung …, 2015 - search.ebscohost.com
Tyrosine kinase inhibitors (TKIs) are the focus in oncology research. As oral drugs, TKIs
often have pH-dependent solubility--suggesting interactions with gastric acid suppressants …

Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer

MP Chu, S Ghosh, CR Chambers… - Clinical lung …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.

MP Chu, S Ghosh, CR Chambers, N Basappa… - Clinical Lung …, 2014 - europepmc.org
Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …